Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer
Shankar Siva, Cristian Udovicich, Ben Tran, Homi Zargar, Declan G Murphy, Michael S Hofman
Nature Reviews Urology | NATURE PUBLISHING GROUP | Published : 2020
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly being established as arguably the leading contemporary imaging modality in the management of prostate cancer. Outside of its conventional use in the de novo staging of localized disease and detection of biochemical recurrence, additional applications for the use of PSMA PET are emerging. Uptake of PSMA tracers in other genitourinary malignancies, particularly renal cell carcinoma, has led to new fields of investigation. Therapeutic delivery of radiolabelled PSMA small molecules has shown considerable promise in advanced prostate cancer. The ability to use the same molecule for imaging and therapy - theran..View full abstract
Awarded by National Health and Medical Research Council
S.S. is supported through a National Health and Medical Research Council Fellowship APP1122347 and Peter Mac Discovery Partner Fellowship.